Author(s):
Vikram V. Nimbalkar, Sakshi A. Bhongal, Nikita R. Dhage, Ganesh D. Barkade
Email(s):
sakshibhongal26@gmail.com
DOI:
10.52711/0974-360X.2025.00232 
Address:
Vikram V. Nimbalkar1, Sakshi A. Bhongal1, Nikita R. Dhage1, Ganesh D. Barkade2
1Department of Pharmacology, Dr. Vithalrao Vikhe Patil Foundation’s College of Pharmacy, Vilad-Ghat, Ahmednagar, Maharashtra, India - 414111.
2Department of Pharmaceutical Chemistry, Dr. Vithalrao Vikhe Patil Foundation’s College of Pharmacy, Vilad-Ghat, Ahmednagar, Maharashtra, India - 414111.
*Corresponding Author
Published In:
Volume - 18,
Issue - 4,
Year - 2025
ABSTRACT:
Cancer is global health problem causing death around the world. Traditional chemotherapy drugs have significant side effects and recent research has proven that the Food and Drug Administration authorized medication mebendazole shows anticancer effects. The present review summarizes mebendazole, as potential anticancer agent. Mebendazole is effective against brain, melanoma, ovariancancer, meningioma cancer, prostate cancer, pancreatic, lung, breast cancer, colorectal cancer. Mebendazole shows its effects through programmed cell death, halt in cell division process, prevention of angiogenesis. It can also act on cancer related mechanisms like, MEK/ERK, AP1, STAT1/2, ELK1/SRF, and MYC/MAX. According to pharmacokinetic profile of mebendazole it has quick first pass metabolism with poor oral bioavailability. Mebendazole treatment, either by itself or combined with other medications, led to a notable decrease in the progression of metastatic disease, improvement in survival, and a reduction or cessation of tumor growth. Mebendazole has anticancer properties against a variety of cancer types, as shown by numerous preclinical investigations and clinical trials.
Cite this article:
Vikram V. Nimbalkar, Sakshi A. Bhongal, Nikita R. Dhage, Ganesh D. Barkade. Repurposing of Mebendazole as an Anticancer Agent: A Review. Research Journal of Pharmacy and Technology. 2025;18(4):1619-4. doi: 10.52711/0974-360X.2025.00232
Cite(Electronic):
Vikram V. Nimbalkar, Sakshi A. Bhongal, Nikita R. Dhage, Ganesh D. Barkade. Repurposing of Mebendazole as an Anticancer Agent: A Review. Research Journal of Pharmacy and Technology. 2025;18(4):1619-4. doi: 10.52711/0974-360X.2025.00232 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-4-23
REFERNCES:
1. Keerthi Priya et.al. In vitro and In vivo Evaluation of Anticancer Properties of Clerodendrum indicum (L.) Kuntze in Colon Cancer. Research Journal of Pharmacy and Technology. 2020; 13: 5 https://doi:10.5958/0974-360X.2020.00418
2. Nanditha et. al. Evaluation of anti-cancer, antioxidant and antimicrobial activities of Alstonia scholaris L. Research Journal of Pharmacy and Technology. 2020; 13: 9. https://doi:10.5958/0974-360X.2020.00733.7.
3. Karpagam T et. al. Anti-Cancer Activity of Aloe Vera Ethanolic Leaves Extract against In vitro Cancer Cells. Research Journal of Pharmacy and Technology. 2019; 12: 5.https://doi:10.5958/0974-360X.2019.00360.3
4. Punna Venkateshwarlu, Mehul M. Patel. A Review: Method Development Validation and Degradation Studies of some Anticancer Drugs. Research Journal of Pharmacy and Technology. 2021; 14: 10. https://doi:10.52711/0974-360X.2021.00949
5. D Saha, D Mridha, S Mondal, M Jana, S Kayal. Organoselenium as a Cancer Chemopreventive Agent against Carcinogenesis. Research Journal of Pharmacy and Technology. 2011; 4: 3
6. Amaq Fadholly, Arif N. M. Ansori, Teguh H. Sucipto. An Overview of Naringin: Potential Anticancer compound of Citrus Fruits. Research Journal of Pharmacy and Technology. 2020; 13: 11. https://doi:10.5958/0974-360X.2020.00979.8
7. Sangeeta S. Tanavade, Smt. Nilofer Naikwade, Dhanyakumar D. Chougule. In vitro anticancer activity of Ethanolic and Aqueous Extracts of Peristrophe bivalvis Merrill. Research Journal of Pharmacy and Technology. 2012; 5: 10.
8. Mukesh K. Nag, Satish Patel, Rajnikant Panik, Shikha Shrivastava, Sanjay J. Daharwal, Manju R. Singh, Deependra Singh Lung Cancer Targeting: A Review. Research Journal of Pharmacy and Technology. 2013; 6: 11
9. Zhang Z et. al. Overcoming cancer therapeutic bottleneck by drug repurposing, Signal Transduction and Targeted Therapy. 2020; 5: 113. https://doi.org/10.1038/s41392-020-00213-8
10. Meco D et. al. Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers. International Journal of Molecular Sciences. 2023; 24: 1334. https://doi.org/10.3390/ijms24021334
11. Hilda Maysarah, Meutia Faradilla, Irma Sari, Didi Nurhadi Illian. Cancer Chemopreventive effect of Rodent Tuber (Typhonium flagelliforme (Lood) Bl) against DMBA-Induced Rats Breast Tumor. Research Journal of Pharmacy and Technology. 2020; 13: 12. https://doi:10.5958/0974-360X.2020.01013.6
12. Anjali Sani, Patel Femida, Preeti Sharma, in-vitro Cytotoxic Activity of Plant Saponin Extracts on Breast Cancer Cell-Line. Research Journal of. Pharmacognosy and Phytochem. 2017; 9: 1 https://doi:10.5958/0975-4385 2017.000036
13. Joe NS et. al., Mebendazole Treatment Disrupts the Transcriptional Activity of Hypoxia-Inducible Factors1and 2 in Breast Cancer Cells. Cancers. 2023; 15: 1330. https://doi.org/10.3390/cancers15041330
14. Daniel JP et. al., Anticancer potential of mebendazole against chronic myeloid leukemia: in silico and in vitro studies revealed new insights about the mechanism of action. Frontiers in Pharmacology. 2022; 13: 952250. https://doi:10.3389/fphar.2022.
15. Williamson Tet. al., Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer. Oncotarget. 2021 ;12. https://doi:10.18632/oncotarget.28014.
16. Mukhopadhyay Tet. al., Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clinical Cancer Research. 2002; 8.
17. Hoofnagle JH. LiverTox: a website on drug-induced liver injury. In Drug-induced liver disease. Academic Press. 2013. https://doi.org/10.1016/B978-0-12-387817-5.00040-6 .
18. Zhang Let. al., Mebendazole potentiates radiation therapy in triple-negative breast cancer. International Journal of Radiation Oncology Biology Physics. 2019; 103. https://doi:10.1016/j.ijrobp.2018.08.046 .
19. Williamson Tet. al., Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model. Oncotarget. 2016; 7: 42. https://doi:10.18632/oncotarget.11851
20. Petersen JS, Baird SK. Treatment of breast and colon cancer cell lines with anti-helmintic benzimidazoles mebendazole or albendazole results in selective apoptotic cell death. Journal of Cancer Research and Clinical Oncology. 2021; 147. https://orcid.org/0000-0001-6741-5866
21. Nygren P, Fryknäs M, Ågerup B, Larsson R. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. Journal of Cancer Research and Clinical Oncology. 2013; 139. https://DOI:10.1007/s00432-013-1539-5
22. Bai RYet. al., Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-oncology. 2011;13. https://doi:10.1093/neuonc/nor077
23. Bai RYet. al., Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro-oncology. 2015; 17. https://doi:10.1093/neuonc/nou234
24. De Witt Met. al., Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors. Molecular Medicine. 2017; 23. https://doi:10.2119/molmed.2017.00011
25. Simbulan-Rosenthal CM et. al., the repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. Oncotarget. 2017; 8: 8. https://doi:10.18632/oncotarget.14990.
26. Skibinski CG, Williamson T, Riggins GJ. Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma. Journal of Neuro-oncology. 2018; 140. https://doi:10.1007/s11060-018-03009-7.
27. Huang Let. al., Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways. Aging (Albany NY). 2021; 13: 13. https://doi:10.18632/aging.203232.
28. Rushworth LK et. al., Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. British Journal of Cancer. 2020; 122(4). https://doi.org/10.1038/s41416-019-0681-5
29. Guerini AE et. al., Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature. Cancers. 2019; 11: 1284. https://doi:10.3390/cancers11091284
30. Jong-Yil Cha et. al., Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update. The Korean Journal of Parasitology. 2021; 59:3. https://doi.org/10.3347/kjp.2021.59.3.189
31. Pushpakom Set al., Drug repurposing: progress, challenges and recommendations. Nature reviews Drug Discovery. 2019; 18. https://doi:10.1038/nrd.2018.168
32. Mohi-Ud-Din Ret. al., Repurposing approved non-oncology drugs for cancer therapy: A comprehensive review of mechanisms, efficacy, and clinical prospects. European Journal of Medical Research. 2023; 28: 345. https://doi.org/10.1186/s40001-023-01275-4
33. Joe NSet. al., Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness. Breast Cancer Research. 2022; 24: 98. https://doi.org/10.1186/s13058-022-01591-3
34. Banovic Pet. al., Drug repurposing: Mebendazole as effective antitumor agent. Are we seeing the whole story. Journal of Balkan Union of Oncology. 2018; 23: 6.
35. Popović DJ et. al., Application of a widely-used tropical anti-worm agent, mebendazole, in modern oncology. Tropical Journal of Pharmaceutical Research. 2017; 16. http://dx.doi.org/10.4314/tjpr.v16i10.32
36. Hamilton G, Rath B. Repurposing of anthelminthics as anticancer drugs. Oncomedicine. 2018; 3. https://doi:10.7150/oncm.20563.
37. Barbosa R, Acevedo LA, Marmorstein R. The MEK/ERK network as a therapeutic target in human cancer. Molecular Cancer Research. 2021; 19. http://doi:10.1158/1541-7786.MCR-20-0687.
38. Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1-to S-phase transition. Oncogene. 2007; 26. http://doi:10.1038/sj.onc.1210414
39. Chambard JC et. al., ERK implication in cell cycle regulation. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2007; 1773. https://doi:10.1016/j.bbamcr.2006.11.010.
40. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Oncology Research and Treatment. (2002) ;25.https://doi:10.1159/000068621.
41. Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Patents on Anti-cancer Drug Discovery. 2009; 4. https://doi:10.2174/157489209787002461.
42. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nature Cell Biology. 2002; 4. https://doi:10.1038/ncb0502-e131.
43. Ameyar M, Wisniewska M, Weitzman JB. A role for AP-1 in apoptosis: the case for and against. Biochimie. 2003; 85. https://doi.org/10.1016/j.biochi.2003.09.006
44. Bossy-Wetzel E, Bakiri L, Yaniv M. Induction of apoptosis by the transcription factor c-Jun. The EMBO Journal. 1997; 16. https://doi:10.1093/emboj/16.7.1695
45. Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduction and Targeted Therapy. 2021; 6: 402. https://doi.org/10.1038/s41392-021-00791-1
46. Jatiani SS, Baker SJ, Silverman LR, Reddy EP. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes and Cancer. 2010; 1. https://DOI:10.1177/1947601910397187
47. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. Journal of Biological Chemistry. 2007; 282. https://doi:10.1074/jbc.R700016200
48. Thomas SJ et. al., The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. British Journal of Cancer. 2015; 113. https://DOI:10.1038/bjc.2015.233
49. MessinaJLet.al., Activated stat-3 in melanoma. Cancer Control. 2008; 15. https://doi.org/10.1177/107327480801500302
50. Groner B, von Manstein V. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Molecular and Cellular Endocrinology. 2017; 451. https://doi.org/10.1016/j.mce.2017.05.033.
51. Sasaki JI et. al., the anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Molecular Cancer Therapeutics. 2002; 1.
52. Pinto LC et. al., Mebendazole, an antiparasitic drug, inhibits drug transporters expression in preclinical model of gastric peritoneal carcinomatosis. Toxicology In vitro. 2017; 43. http://dx.doi.org/10.1016/j.tiv.2017.06.007
53. Pinto LC et. al., the anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model. Toxicology in Vitro. 2015; 29. http://dx.doi.org/10.1016/j.tiv.2015.08.007
54. Bai RYet. al., Brain penetration and efficacy of different mebendazole polymorphs in a mouse brain tumor model. Clinical Cancer Research. 2015; 21. http://doi:10.1158/1078-0432.CCR-14-2681.
55. Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Tropica. 2003; 86. https://doi:10.1016/S0001-706X(03)00031-7
56. Pantziarka Pet. al., Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent. Ecancermedical Science. (2014); 8. https://doi:10.3332/ecancer.2014.443
57. Mansoori Set. al., A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer. Scientific Reports. 2021; 11: 8981. https://doi.org/10.1038/s41598-021-88433-y
58. https://classic.clinicaltrials.gov/ct2/show/NCT01837862
59. Zhang F et. al., Anthelmintic mebendazole enhances cisplatin’s effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC). Oncotarget. 2017; 8: 12968. https://doi.org/10.18632/oncotarget.14673